Q41-50: Post-HCT / Post-Infusion Therapy

Question 41: Was therapy given since the date of last report for reasons other than relapse or persistent disease?

Indicate if the recipient received treatment post-infusion for reasons other than relapse or persistent disease during the current reporting period. Recipients generally receive a HCT / cellular therapy under a specific protocol which defines radiation and / or systemic therapy to be given prior to infusion; prophylactic medications to be administered pre- and / or post-infusion; as well as any systemic therapy, radiation, and / or other treatments to be administered post-infusion as planned (or maintenance) therapy. Planned (maintenance) therapy is given to assist in prolonging a remission. Planned therapy may be described in a research protocol or standard of care protocol. Refer to these documents (if available) when completing this section. If post-infusion therapy is given as prophylaxis or maintenance for recipients in CR, report the therapy in questions 41-50. Do not include any treatment administered as a result of relapse or persistent disease (including treatment for minimal residual disease).

If therapy was given for reasons other than relapse or persistent disease during the reporting period, report “Yes” and go to question 42. If “No” or “Unknown,” go to question 51.

Question 42: Central nervous system irradiation

Radiation therapy includes high-energy x-rays, gamma rays, electron beams, or proton beams to kill cancer cells. Radiation therapy may be used to kill cells that have invaded other tissues and lymph nodes. If the recipient received radiation targeting part or all of the central nervous system (excluding total body irradiation) during the reporting period for reasons other than relapse or persistent disease, report “Yes.” If not, report “No.”

Question 43: Systemic therapy

!Intrathecal Therapy
Intrathecal therapy given for reasons other than minimal residual disease, persistent disease, or relapse must be reported as “Systemic therapy” in questions 43-47. Specifically, if a recipient receives intrathecal therapy during the reporting period for reasons other than minimal residual disease, persistent disease, or relapse, answer question 43 “Yes” and select “Intrathecal therapy” under question 46.

Systemic therapy includes chemotherapy, immunotherapy, or targeted therapies delivered via the blood stream and distributed throughout the body. Therapy may be injected into a vein or given orally. Do not report total body irradiation or subsequent HCT / cellular therapies in questions 43-47. If the recipient received systemic therapy during the reporting period for reasons other than relapse or persistent disease, report “Yes” and go to question 44. If not, report “No” and go to question 48.

Question 44-45: Date therapy (maintenance) was first started post-HCT / post- infusion

*Form Revision Change
If maintenance therapy was started during a prior reporting period, for which, an AML Post-HCT Data Form Revision 3 was completed, the start date will not have been reported on that form. In this case, report the date maintenance therapy was started on the current form (AML Post-Infusion Data Form, Revision 4) and override the validation error using the code “Verified Correct.” If the reported maintenance therapy continues into the next reporting period, the site will indicate “Previously reported” in question 44.

If the recipient started systemic therapy for reasons other than relapse or persistent disease during the reporting period, report “Known” for question 44 and indicate the date started in question 45. If the exact date is not known, use the process for reporting partial or unknown dates as described in the General Instructions, Guidelines for Completing Forms.

If the recipient started therapy for reasons other than relapse or persistent disease in a prior reporting period and continued the therapy into the current reporting period, report “Previously reported” and go to question 46.

For recipients who start and stop therapy multiple times post-infusion, first determine whether the recipient stopped therapy for at least 30 days. If not, consider the therapy continuous. Only report a new therapy start date if all three of the below conditions are met.

1. The recipient stopped all therapy given for reasons other than relapse or persistent disease during a prior reporting period; and
2. The recipient restarted therapy for reasons other than relapse or persistent disease during the current reporting period; and
3. Therapy was restarted at least 30 days after the therapy stop date.

Question 46-47: Specify systemic therapy given

Select all systemic therapy (see question 43 for definition) given for reasons other than relapse or persistent disease during the reporting period. If a therapy is given, but not listed as an option in question 46, select “Other systemic therapy” and specify the drug in question 47.

Question 48: Cellular therapy

Cellular therapy treatment strategies include isolation and transfer of specific stem cell populations, administration of effector cells (e.g., cytotoxic T-cells), induction of mature cells to become pluripotent cells, and reprogramming of mature cells (e.g., CAR T-cells). Do not report a HCT as a cellular therapy in question 48.

Report “Yes” if the recipient received cellular therapy for reasons other than relapse or persistent disease during the reporting period. If not, report “No.”

Question 49-50: Other therapy

Indicate if the recipient received any other therapy (not already reported in questions 42-48) given for reasons other than relapse or persistent disease during the reporting period. Do not report HCT in questions 49-50. If “Yes,” specify all other therapies given in question 50. If “No,” go to question 51.

Section Updates:

Question Number	Date of Change	Add/Remove/Modify	Description	Reasoning (If applicable)
.	.	.	.	.

Copyright © 2004-2024 The Medical College of Wisconsin, Inc. and NMDP. All Rights Reserved.
CIBMTR® (Center for International Blood and Marrow Transplant Research) is a research collaboration between the Medical College of Wisconsin and NMDP.